MAPK8 and idiopathic pulmonary fibrosis: Finally, a clinical trial of CC-930 (the pan-JNK inhibitor used in our study) in patients with idiopathic pulmonary fibrosis (NCT01203943) was terminated due to an unfavorable benefit/risk profile.